CN104138450A - Schisandra extract for treating cough and relieving airway inflammation as well as preparation method and application of schisandra extract - Google Patents
Schisandra extract for treating cough and relieving airway inflammation as well as preparation method and application of schisandra extract Download PDFInfo
- Publication number
- CN104138450A CN104138450A CN201410387092.3A CN201410387092A CN104138450A CN 104138450 A CN104138450 A CN 104138450A CN 201410387092 A CN201410387092 A CN 201410387092A CN 104138450 A CN104138450 A CN 104138450A
- Authority
- CN
- China
- Prior art keywords
- extract
- fructus schisandrae
- cough
- schisandrae chinensis
- schisandra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a schisandra extract for treating cough and relieving airway inflammation as well as a preparation method and application of the schisandra extract. The preparation method comprises the steps of with schisandra as a raw material, carrying out reflux extraction three times by using ethanol, mixing the extracting solutions, and filtering after standing to obtain an extract A, wherein each extraction operation lasts for 1-3h; decocting dregs in water three times, mixing the extracting solutions, and filtering after standing to obtain an extract B, wherein each decoction operation lasts for 1-3h; and mixing the extracts A and B, and carrying out vacuum drying to obtain the schisandra extract. The preparation method provided by the invention is simple and convenient in processing technology, and a solvent is safe, nontoxic and low in price. The schisandra extract prepared by using the preparation method has exact treating and relieving effects for cough, can be used for relieving airway inflammation and can be used for preparing drugs and/or healthcare products for treating cough and relieving airway inflammation.
Description
Technical field
The present invention relates to a kind of Chinese medicine extract, be specifically related to a kind of Fructus Schisandrae Chinensis extrat and its preparation method and application, belong to technical field of Chinese medicines.
Background technology
Cough is the modal symptom of internal clinic, sees various respiratory system and non-respiratory system disease.Cough itself is a kind of defense mechanism, removes secretions too much in air flue and prevents that foreign body from sucking air flue by mistake.But chronic cough has for a long time had a strong impact on patient's quality of life and caused the psychological burden that patient is serious, individual and public medical and health expenditure have also significantly been increased simultaneously.Chronic cough refers to cough into unique symptom or cardinal symptom clinically, and Cough length surpasses 8 weeks, the symptom of chest X-ray Non Apparent Abnormality.The investigation that Guangzhou Inst. of Respiratory Diseases carries out shows, Chronic Cough Patients average course of disease is 3 years, some decades-longs, and medical average time reaches 18 times, average 3 of medical medical institutions, wherein female patient brings out urinary incontinence ratio up to 48% because coughing.In recent years along with the increasing the weight of gradually of air environmental pollution (as PM2.5, PM10 etc.), life stress strengthen, the sickness rate of chronic cough has the trend of rising: many parts of sick learning of Foreign Epidemic studies show that chronic cough is at general population's sickness rate approximately 9%～33%, the Epidemiological study of 2003 Nian Yixiang Britain shows, chronic cough reaches 12% at the middle age sickness rate in 50-59 year, and Chronic Cough Patients accounts for breathes medical expert's consultation patient's 20%.In China, according to Guangzhou Inst. of Respiratory Diseases's statistics, in young university students crowd, the prevalence of chronic cough surpasses 3%, infers that the cough prevalence of community-based population will be far above these data.Chronic Cough Patients carries out various insignificant inspections repeatedly, uses various antibiotic and antitussive medicine treatment all invalid, has a strong impact on patient's physical and mental health and Working Life, and causes the significant wastage of public health resources.
Fructus Schisandrae Chinensis is Magnoliacea plant, fruit medicine, and sour in the mouth, sweet, warm in nature.Return lung, the heart, kidney channel.On tcm clinical practice often by Fructus Schisandrae Chinensis compatibility cough relief traditional Chinese medicine as Herba Ephedrae, Radix Asteris, Flos Farfarae etc., for dry cough without phlegm or chronic cough cough due to deficiency of the lung's disease endlessly in the later stage of coughing.So far, there is not bibliographical information Fructus Schisandrae Chinensis extrat whether can effectively treat the especially chronic cough of coughing always.
Summary of the invention
In order to address the above problem, the invention provides a kind of preparation method of Fructus Schisandrae Chinensis extrat, the Fructus Schisandrae Chinensis extrat that the present invention makes can be applicable to treatment cough and alleviates airway inflammation.
The present invention takes following steps to prepare Fructus Schisandrae Chinensis extrat:
1) get schisandra chinensis medicinal material, after being dried, pulverize, by alcoholic solution reflux, extract, 1～3 time, each extraction 1～3 hour, each volume (ml) that extracts alcoholic solution used is 4～8 times (that is, every 1g schisandra chinensis medicinal material adds the alcoholic solution of 4～8ml to extract) of schisandra chinensis medicinal material quality (g), merge extractive liquid,, then standing filtration, obtains extract A;
2) by step 1) extract the medicinal residues water stay and decoct 1～3 time, decoct 1～3 hour at every turn, the volume (ml) that at every turn decocts water used is schisandra chinensis medicinal material quality (g) 4～8 times, merge extractive liquid,, then standing filtration, obtains extract B;
3) combining step 1) extract extract A and the step 2 obtain) extract the extract B obtaining, then carry out vacuum drying, make described Fructus Schisandrae Chinensis extrat.
Described schisandra chinensis medicinal material is at least one in Fructus Schisandrae Chinensis Schisandra chinensis (Turcz.) Baill. or schisandra chinensis Schisandra sphenanthera Rehd.et Wils.
It is the ethanol water of ethanol volumetric concentration between 50-100% for described alcoholic solution.
Further, step 1) in, schisandra chinensis medicinal material crushed after being dried is become to 10～60 orders.
Preferably, in step 1) extracting solution that obtains merge and standing filtration after, also there is the step of filtrate being carried out to concentrating under reduced pressure; In step 2) extracting solution that obtains merge and standing filtration after also there is the step of filtrate being carried out to concentrating under reduced pressure.
Fructus Schisandrae Chinensis extrat of the present invention, its preparation method is simple, equipment cost is low, energy consumption consumption less, solvent safety is nontoxic, cheap, can realize suitability for industrialized production, be easy to promote.
The compositions that the present invention also provides the Fructus Schisandrae Chinensis extrat of being prepared by said method or contains described Fructus Schisandrae Chinensis extrat is in the medicine of preparation treatment cough and/or the application in health product, and described cough comprises acute, subacute or chronic cough.The Fructus Schisandrae Chinensis extrat that the present invention makes has antitussive effect, to coughing, relevant airway inflammation and cough hypersensitivity are inhibited.
Fructus Schisandrae Chinensis extrat of the present invention can be applied separately, also can add suitable pharmaceutic adjuvant, makes various medicine or the health product that pharmaceutically allow dosage form such as soft capsule, hard capsule, tablet, granule, drop pill, watered pill, honey pill agent, oral liquid.
Fructus Schisandrae Chinensis extrat of the present invention can also form Chinese medicine composition with other Chinese medicine extract, add suitable pharmaceutic adjuvant, make various medicine or the health product that pharmaceutically allow dosage form such as soft capsule, hard capsule, tablet, granule, drop pill, watered pill, honey pill agent, oral liquid.
Accompanying drawing explanation
Fig. 1 is embodiment 4 guinea pig lung tissues and air flue pathological section representative graph (HE * 200)
Fig. 2 is the impact of Fructus Schisandrae Chinensis extrat different time points on citric acid smoke stimulation guinea pig cough number of times
The specific embodiment
Following examples are used for illustrating the present invention, but are not used for limiting category of the present invention.
Embodiment 1:
Dry Radix Schisandrae Bicoloris medical material 10kg, be ground into 30 order coarse powder, with 95% (v/v) alcohol reflux 3 times, each 3h, the volume (ml) that extracts ethanol used for three times is respectively 8 times, 6 times, 6 times of quality of medicinal material (g), merges 3 times extracting solution, standing rear filtration, concentrating under reduced pressure, obtains extract A; The medicinal residues decocting staying after extracting is boiled 2 times, each 2h, the volume of the twice required water of decoction (ml) is respectively 8 times, 6 times of schisandra chinensis medicinal material quality (g), merges 2 times extracting solution, standing rear filtration, concentrating under reduced pressure, obtains extract B.United extraction thing A and B, vacuum drying, obtains Fructus Schisandrae Chinensis extrat 5.69kg.
Embodiment 2:
Dry Fructus Schisandrae Sphenantherae medical material 10kg, be ground into 40 order coarse powder, 80% (v/v) ethanol water reflux, extract, 3 times, each 3h, the volume (ml) that extracts ethanol for three times is respectively 8 times, 6 times, 6 times of schisandra chinensis medicinal material quality (g), merges 3 times extracting solution, standing rear filtration, concentrating under reduced pressure, obtains extract A; The medicinal residues decocting staying after extraction boils 2 times, each 2h, and the volume (ml) that decocts water for twice is respectively 8 times, 6 times of schisandra chinensis medicinal material quality (g), merges 2 times extracting solution, standing rear filtration, concentrating under reduced pressure, obtains extract B.United extraction thing A and B, vacuum drying, obtains Fructus Schisandrae Chinensis extrat 5.28kg.
Embodiment 3:
Dry Radix Schisandrae Bicoloris medical material 10kg, be ground into 50 order coarse powder, 60% (v/v) ethanol water reflux, extract, 2 times, each 3h,, the volume of extracted twice ethanol (ml) is respectively 8 times, 6 times of schisandra chinensis medicinal material quality (g), merge extractive liquid,, standing rear filtration, concentrating under reduced pressure, obtains extract A; The medicinal residues decocting that extraction stays boils 2 times, each 2h, and the volume (ml) that decocts water for twice is respectively 8 times, 6 times of schisandra chinensis medicinal material quality (g), merge extractive liquid,, standing rear filtration, concentrating under reduced pressure, obtains extract B.United extraction thing A and B, vacuum drying, obtains Fructus Schisandrae Chinensis extrat 5.42kg.
Embodiment 4:
laboratory animal
Pure white Hartly Cavia porcellus, regular grade, male, body weight 300 ± 50 g, purchased from Guangdong Province's Experimental Animal Center, credit number: SCXK (Guangdong) 2008-0002.Raise the animal center in National Key Laboratory of Guangzhou Inst. of Respiratory Diseases, credit number: SYXK (Guangdong) 2008-0093.Cavia porcellus is raised in relatively clean, peace and quiet, constant temperature (23 ± 3 ℃), constant humidity (55 ± 15%) environment, and day and night the cycle is 12:12 hour/day, and sub-cage rearing, can freely obtain food and water by 5/cage.
medicine and reagent
Fructus Schisandrae Chinensis water extract (make according to following flow process: schisandra chinensis medicinal material is pulverized → 8 times of water gagings and decocted 2h, decoct altogether 3 times → decoction liquor concentrated, dry → Fructus Schisandrae Chinensis water extract); 0.9% sodium chloride injection: Dongguan Pu Ji pharmaceutcal corporation, Ltd.Pentobarbital sodium: U.S. Merck company.Codeine: Industries, Inc of traditional Chinese medicines group." red rose " board cigarette with filter tip: Guangzhou Zhong Yan Industrial Co., Ltd.Other conventional reagent: Guangzhou Chemical Reagent Factory.
In the specific embodiment, all data represent with " means standard deviation ", between each group, relatively adopt spss13.0 to carry out one factor analysis of variance, variance is used least significant difference method (LSD) together, heterogeneity of variance or nonnormal data acquisition rank test, P < 0.05 represents that difference has statistical significance.
experimental apparatus
PM type list chamber unrestricted type petty action object is retouched instrument (1.0 L): U.S. Buxco company; Digital photography integral system: Japanese Nikon company; 0.6m * 0.6m * 1m smoke from cigarette toxicant exposure box: this laboratory self-control; A1003 electronic balance: German Satorius company; MDF-U53V-80 ℃ of cryogenic refrigerator: SANYO GS company; 3-18K SIGMA High speed refrigerated centrifuge: U.S. Beckman company; 22 G venous detaining needles: Suzhou Medical Devices Co., Ltd.; The common high speed centrifuge of Anke TGL-16B type: Town in Shanghai stops scientific instrument factory; The desk-top refrigerated centrifuge of 400 type: German Heraeus company; XW80A type vortex agitator: Shanghai precision instrumentation company limited; DK8A thermostat water bath: go up the grand test apparatus of Nereid company limited.
(1) Fructus Schisandrae Chinensis extrat of embodiment 1 preparation stimulates and causes the pharmacological action that Cough reflex sensitivity increases Cavia porcellus (CS Cavia porcellus) smoke from cigarette
Fume smoking method: Cavia porcellus is raised after one week in experiment prospective adaptation is quiet, be placed in self-control medicated cigarette toxicant exposure box, light 10 medicated cigarettes (fire-cured tobacco type in sootiness groove at every turn, tar content 12mg, smoking nicotine content 1.1mg, carbon monoxide in flue gas content 15mg), by three-way valve, smoke from cigarette is squeezed in toxicant exposure box, from medicated cigarette burning-out, started timing.Each fumigation 20 minutes, every day, fumigation was 2 times, and every secondary fumigation is greater than 6 hours interval time, and fumigation is 14 days continuously.
Experiment: Cavia porcellus completely random is divided into normal group, model group, solvent control group (0.5% PEG400), codeine group, water extract high dose group (dosage 500mg/kg Cavia porcellus/sky, drug level 50mg/mL), Fructus Schisandrae Chinensis extrat high dose group (dosage 500mg/kg Cavia porcellus/sky, drug level 50mg/mL), dosage group (dosage 250mg/kg Cavia porcellus/sky in Fructus Schisandrae Chinensis extrat, drug level 25mg/mL), Fructus Schisandrae Chinensis extrat low dose group (dosage 125mg/kg Cavia porcellus/sky, drug level 12.5mg/mL).
Except normal group, all the other each treated animals all adopt above-mentioned fume smoking method to stimulate.Except normal group and codeine group, all the other respectively organize Cavia porcellus from sootiness first day, and the first 2 hours per os of sootiness for the second time every day give corresponding medicine or solvent, continuous 14 days.Codeine group checks first 1 hour in citric acid Cough reflex sensitivity, oral administration (30mg/kg Cavia porcellus, codeine concentration 3mg/mL).Normal group is normally raised, and does not do any processing.Cavia porcellus was placed in to body in the 15th day and retouches in case, adapt to after 2min, atomization 0.4mol/L citric acid is coughed and is excited, and after 10min, atomization finishes, and continues to observe 10min, guinea pig cough's total degree and cough latent period in the 20min that record starts from atomization.
After cough excitation experiment 24h, 3% pentobarbital sodium solution (1mL/kg) intraperitoneal injection of anesthesia animal, heart extracting blood 10mL.Get the PBS buffer of 6mL 0.1mol/L pre-cooling, minute carry out alveolar wass 3 times, the left lung of unified lavation, lavation 3 times repeatedly, obtains bronchoalveolar lavage fluid (Bronchoalveolar Lavage Fluid, BALF) at every turn.By gained BALF concussion suspendible, extract 0.5mL, with the abundant cracking of erythrocyte cracked liquid, 3000 revs/min centrifugal 10 minutes, get 10 μ L supernatant and splash into blood cell counting plate, under optical microscope, calculate BALF inflammatory cell sum (total cellular score/mL=(four large lattice total cellular score/4) * 10
4/ mL), after extracting 0.5mL, remaining BALF is in the centrifugal 10min of 3000rpm, precipitation 1mLPBS suspendible, get 100 μ L and make cell smear, natural air drying, be soaked in 10% neutral formalin, spend the night fixing, after taking-up, carry out successively flowing water and rinse 10min, haematoxylin dyeing 15sec, flowing water rinses 1min, 1% hydrochloride alcohol decolouring 2sec, flowing water rinses 10min, 5 sec dye in Yihong, flowing water rinses 10min, dry, obtain neutral gum mounting, under optical microscope, continuous counter is carried out in 20 400 times of visuals field of continuous random extraction, 400 cells of every smear continuous counter, calculate wherein neutrophilic granulocyte, eosinophilic granulocyte, macrophage, lymphocytic ratio.
Cavia porcellus extracts after BALF, injects 50mL PBS carry out lavation from heart, from trachea, injects 2.5mL4% paraformaldehyde, then bottom right lung tissue of clip and one section of trachea, and 10% neutral formalin is fixedly more than 24h.Take out the lung tissue having fixed, carry out successively Gradient elution using ethanol, biological clarifier processing, waxdip, embedding, section, dewaxing, gradient ethanol aquation, the of short duration rinsing of distilled water, finally carry out after HE dyeing, neutral gum mounting, carries out pathological observation.
Experimental result: with normal group comparison, each experimental group Guinea Pig Airway resistance has no notable difference, points out this Experimental Modeling not cause Guinea Pig Airway resistance increment, is different from chronic obstructive pulmonary disease animal model.
Each experimental group Cavia porcellus citric acid excites cough number of times in Table 1.Result shows, with model group comparison, Fructus Schisandrae Chinensis extrat (high, medium and low dosage group) all can significantly reduce the cough number of times of model guinea pigs.
The Fructus Schisandrae Chinensis extrat of table 1 embodiment 1 preparation on the impact of CS guinea pig cough number of times (
) (n=7)
Note: with normal group comparison: * * P<0.01; With model group comparison: #P<0.05, ##P<0.01
Each experimental group Cavia porcellus citric acid cough excitation experiment cough latent period is in Table 2.Result shows, with model group comparison, and the high, medium and low dosage group cough latent period significant prolongation of Fructus Schisandrae Chinensis extrat; Water extract high dose is not obvious to the effect of cough latent period.
The Fructus Schisandrae Chinensis extrat of table 2 embodiment 1 preparation on the preclinical impact of CS guinea pig cough (
) (n=7)
Note: with normal group comparison: * * P<0.01; With model group comparison: #P<0.05, ##P<0.01
In each experimental group animal bronchoalveolar lavage fluid, inflammatory cell sum and classification comparative experiments the results are shown in Table 3.Result shows, with model group comparison, the high, medium and low dosage of Fructus Schisandrae Chinensis extrat all can significantly reduce inflammatory cell sum in BALF, significantly reduce neutrophilic granulocyte ratio in BALF.Water extract high dose is not obvious to inflammatory cell sum in BALF and neutrophilic granulocyte proportional action.
The Fructus Schisandrae Chinensis extrat of table 3 embodiment 1 preparation on the impact of CS guinea pig bronchial bronchoalveolar lavage fluid inflammatory cell sum and classification (
) (n=7)
Note: with normal group comparison: * * P<0.01; With model group comparison: #P<0.05, ##P<0.01
With model group comparison, each dosage group guinea pig lung tissue of Fructus Schisandrae Chinensis extrat of the present invention and trachea pathology all obviously improve: Cavia porcellus peribronchiolitis disease cellular infiltration obviously reduces, in tube chamber, ooze out and alleviate, alveolar septum broadening degree is lighter, and the Fructus Schisandrae Chinensis extrat that prompting the present invention makes can significantly alleviate airway inflammation of guinea.And water extract high dose group guinea pig lung tissue and the improvement of trachea pathology are not obvious.Each experimental group guinea pig lung tissue and trachea pathological section representative graph are shown in accompanying drawing 1.
(2) Fructus Schisandrae Chinensis extrat of embodiment 2 preparations causes the pharmacological action of acute cough Cavia porcellus to citric acid smoke stimulation
Cavia porcellus rested after one week, carried out Cough reflex sensitivity screening: the atomization of 0.8mol/L citric acid stimulates 1min, stops atomization, continued to observe 5min, the cough number of times of record in atomization starts 6min, and being greater than and being less than the Cavia porcellus of 50 times for 10 times is qualified Cavia porcellus.
The qualified Cavia porcellus completely random of screening is divided into normal group, solvent control group (0.5% PEG400), codeine group, water extract high dose group (dosage 500mg/kg Cavia porcellus/sky, drug level 50mg/mL), Fructus Schisandrae Chinensis extrat high dose group (dosage 500mg/kg Cavia porcellus/sky, drug level 50mg/mL), dosage group (dosage 250mg/kg Cavia porcellus/sky in Fructus Schisandrae Chinensis extrat, drug level 25mg/mL), Fructus Schisandrae Chinensis extrat low dose group (dosage 125mg/kg Cavia porcellus/sky, drug level 12.5mg/mL).Except normal group and codeine group, all the other are respectively organized Cavia porcellus per os continuous 5 day every day and give medicine or solvent, 1 times/day, after administration on the 5th or solvent, 1h carries out citric acid cough and excites: the atomization of 0.8mol/L citric acid stimulates 1min, stop atomization, continue to observe 5min, the cough number of times of record in atomization starts 6min.Codeine group excites first 1 hour oral administration in citric acid cough on the 5th.Normal group is normally raised, and within 5th, directly carries out citric acid cough and excites.
The cough number of times of each experimental group is as shown in table 5.Result shows, with normal group comparison, guinea pig cough's number of times of the high, medium and low dosage intervention group of Fructus Schisandrae Chinensis extrat all significantly reduces, and water extract high dose group guinea pig cough number of times is without significant difference.
The Fructus Schisandrae Chinensis extrat of table 5 embodiment 2 preparation on citric acid cause acute cough guinea pig cough number of times impact (
) (n=7)
Note: with normal group comparison: * P<0.05, * * P<0.01
The cough latent period of each experimental group is as shown in table 6.Result shows, with normal group comparison, and the equal significant prolongation of cough latent period of the high, medium and low dosage group of Fructus Schisandrae Chinensis extrat Cavia porcellus.The cough latent period of water extract high dose group Cavia porcellus and normal group are without significant difference.
The Fructus Schisandrae Chinensis extrat of table 6 embodiment 2 preparation on citric acid cause the preclinical impact of acute cough guinea pig cough (
) (n=7)
Note: with the comparison of solvent control group: * P<0.05, * * P<0.01
(3) Fructus Schisandrae Chinensis extrat of embodiment 3 preparations causes the ageing of acute cough Cavia porcellus to citric acid smoke stimulation
Cavia porcellus rested after one week, carried out Cough reflex sensitivity screening: the atomization of 0.8mol/L citric acid stimulates 1min, stops atomization, continued to observe 5min, the cough number of times of record in atomization starts 6min, and being greater than and being less than the Cavia porcellus of 50 times for 10 times is qualified Cavia porcellus.
Screen the normal raising of qualified Cavia porcellus after 3 days, be divided at random 4 large groups, 30 of every large groups.First group is divided into 3 groups at random, and 10 of every groups all directly carry out citric acid cough and excite: the atomization of 0.8mol/L citric acid stimulates 1min, stops atomization, continue to observe 5min, the cough number of times of record in atomization starts 6min.Second largest group is divided into 3 groups at random: normal group, codeine group (30mg/kg, oral administration), the Fructus Schisandrae Chinensis extrat group (250mg/kg of embodiment 3 preparations, drug level 25mg/mL, oral administration), 10 of every groups, normal group is directly carried out citric acid cough and is excited, and codeine group and the administration of Fructus Schisandrae Chinensis extrat group were coughed and excited after 1 hour, and shooting condition is with first group; The third-largest group all identical with second largest group with grouping and the shooting condition of the fourth-largest group, and codeine group and Fructus Schisandrae Chinensis extrat group administration time are respectively and excite front 3h and 5h.
Result as shown in Figure 2, show that can significantly reduce citric acid smoke stimulation after Fructus Schisandrae Chinensis extrat (250mg/kg) the once daily 1h of embodiment 3 preparation causes Cavia porcellus acute cough number of times, and after administration 5h, still can show significant drug effect, and codeine is coughed after administration 5h, number of times and normal group are without significant difference.
The pharmacological experiments of Fructus Schisandrae Chinensis extrat prepared by 3 embodiment shows, the Fructus Schisandrae Chinensis extrat energy significant prolongation CS Cavia porcellus that the present invention makes and citric acid stimulate the cough latent period that causes acute cough Cavia porcellus, reduce cough number of times, significantly reduce inflammatory cell sum and neutrophilic granulocyte ratio in CS Cavia porcellus bronchoalveolar lavage fluid, after the Fructus Schisandrae Chinensis extrat intervention that pathology section examination prompting the present invention makes, Cavia porcellus peribronchiolitis disease cellular infiltration obviously reduces, in tube chamber, ooze out and alleviate, alveolar septum broadening degree alleviates, point out Fructus Schisandrae Chinensis extrat of the present invention to there is significant inhibitory action to the airway inflammation of Cavia porcellus.And the effect of Fructus Schisandrae Chinensis extrat prepared by the present invention is significantly better than Fructus Schisandrae Chinensis water extract, and be a certain amount of effect relationship, show antitussive, relieving cough and alleviate the application prospect of airway inflammation aspect.
Embodiment 5:
Get the Fructus Schisandrae Chinensis extrat 1kg of embodiment 2 preparations, by suitable quantity of water, heated and boiled is dissolved, and makes Fructus Schisandrae Chinensis extrat solution, standby; Separately get sucrose 1kg, add water boil, add the Fructus Schisandrae Chinensis extrat solution having prepared above, add wherein sodium benzoate 4 g, mix simultaneously, standing, get supernatant, add pure water to 4000mL, mix, filter, sterilizing, every bottle of 100ml subpackage, makes the syrup of Fructus Schisandrae Chinensis extrat.
Instructions of taking that can be for reference is: every day 1-3 time, each 20ml.
Embodiment 6:
The Fructus Schisandrae Chinensis extrat syrup that embodiment 5 makes is through clinical experiment, wherein there are Chronic Cough Patients 15 example and acute cough patient's 15 examples, by drinking the syrup 1～3 time that embodiment 5 makes every day, each 20mL, take continuously 1～2 week, total effective rate is 100%, and concrete feedback result can see the following form:
| Case | Effective | Effectively | Invalid |
| Acute cough | 12 | 3 | 0 |
| Chronic cough | 11 | 4 | 0 |
Below just wherein 4 model cases describe in detail:
Case 1: Zhang, man, 55 years old, cough about 4 months, be diagnosed as the high quick syndrome of cough, take continuously the Fructus Schisandrae Chinensis extrat syrup one week that embodiment 5 makes, Cough reflex sensitivity significantly lowers, and cough number of times significantly reduces.
Case 2: Liu, female, 35 years old, cough about 2 months, be diagnosed as postinfectious cough, take 2 bottles, the Fructus Schisandrae Chinensis extrat syrup that embodiment 5 makes, the first day onset of taking medicine, takes 2 bottles cough is basic afterwards and alleviate.
Case 3: Bao, female, 41 years old, coughs about 1 month, the stifled sense of companion's expectorant, the difficult expectoration of expectorant, is diagnosed as postinfectious cough, takes 2 bottles, the Fructus Schisandrae Chinensis extrat syrup that embodiment 5 makes, second day onset after taking medicine, takes 2 bottles and coughs and take a turn for the better 7 one-tenth afterwards, adds after 1 bottle, and cough is alleviated substantially completely.
Case 4: especially certain, man, 24 years old, coughs about 2 years, dry cough is main, is diagnosed as eosinophilic granulocyte's property bronchitis, and gastroesophageal reflux induced cough is taken 2 bottles, the Fructus Schisandrae Chinensis extrat syrup that embodiment 5 makes, the onset in the 3rd day of taking medicine, cough takes a turn for the better 4 one-tenths, adds after 2 bottles, and the symptom of coughing is eliminated substantially.
From above-described embodiment, only, by just effective relieving cough of oral Fructus Schisandrae Chinensis extrat syrup of the present invention, alleviate airway inflammation.And Fructus Schisandrae Chinensis extrat that the present invention makes extracts from Chinese medicine Schisandra chinensis, Fructus Schisandrae Chinensis is the Chinese medicine that can be used for health food that Ministry of Public Health is announced, to human body without any toxicity and side effect.
Fructus Schisandrae Chinensis extrat of the present invention is except making syrup, those skilled in the art also can adopt existing preparation process to be made into pharmaceutically acceptable other dosage forms, such as tablet, hard capsule, soft capsule, powder, tincture, pill, granule, injection or other oral liquid formulations etc. as required.For example granulation agent by the following method: Fructus Schisandrae Chinensis extrat prepared by the present invention and supplementary product starch, sucrose and disintegrating agent mix, again mixture is added with mixing in water-soluble adhesive fiber element derivative solution, adopt extrusion granulator method that medicine is made to soft grit, drying, sieve, oversize is suitably pulverized, after sieve, can be made into single-size.Also can make by the following method tablet: Fructus Schisandrae Chinensis extrat of the present invention and appropriate amount of starch, Pulvis Talci are mixed, and moistening with 70% ethanol, granulation, then uses tablet machine tabletting, thereby makes Fructus Schisandrae Chinensis extrat sheet.Also can, by add appropriate carboxymethyl cellulose, cyclodextrin in Fructus Schisandrae Chinensis extrat of the present invention, prepare Fructus Schisandrae Chinensis extrat capsule.These preparation process are the art prior art, and this is no longer going to repeat them.
The above, it is only preferred embodiment of the present invention, not the present invention is done to any pro forma restriction, the content that does not depart from technical solution of the present invention therefore all, according to technical spirit of the present invention, to any simple modification made for any of the above embodiments, equivalent variations and modification, all still belong in the scope of technical solution of the present invention.
Claims (10)
1. for the preparation of a method for the treatment of the Fructus Schisandrae Chinensis extrat of cough and alleviation airway inflammation, it is characterized in that, comprise the steps:
1) get schisandra chinensis medicinal material, after being dried, pulverize, by alcoholic solution reflux, extract, 1～3 time, each extraction 1～3 hour, each volume (ml) that extracts alcoholic solution used is 4～8 times of schisandra chinensis medicinal material quality (g), merge extractive liquid,, then standing filtration, obtains extract A;
2) by step 1) extract the medicinal residues water stay and decoct 1～3 time, decoct 1～3 hour at every turn, the volume (ml) that at every turn decocts water used is schisandra chinensis medicinal material quality (g) 4～8 times, merge extractive liquid,, then standing filtration, obtains extract B;
3) combining step 1) extract extract A and the step 2 obtain) extract the extract B obtaining, then carry out vacuum drying, make described Fructus Schisandrae Chinensis extrat.
2. method according to claim 1, it is characterized in that, described schisandra chinensis medicinal material is at least one in Fructus Schisandrae Chinensis Schisandra chinensis (Turcz.) Baill. or schisandra chinensis Schisandra sphenanthera Rehd.et Wils..
3. method according to claim 1, is characterized in that, it is the ethanol water of ethanol volumetric concentration between 50-100% for described alcoholic solution.
4. method according to claim 1, is characterized in that step 1) in, schisandra chinensis medicinal material crushed after being dried is become to 10～60 orders.
5. method according to claim 1, is characterized in that step 1) and/or step 2) after the standing filtration of extracting solution obtaining separately, also there is the step of filtrate being carried out to concentrating under reduced pressure.
6. the Fructus Schisandrae Chinensis extrat being made by the method described in claim 1～5 any one.
7. the Fructus Schisandrae Chinensis extrat that the method described in claim 1～5 any one makes for the preparation for the treatment of acute, subacute or the medicine of chronic cough or the application in health product.
8. application according to claim 7, is characterized in that, described Fructus Schisandrae Chinensis extrat is applied in the medicine for the preparation of antitussive, relieving cough or alleviation airway inflammation or health product.
9. according to the application described in claim 7 or 8, it is characterized in that, described Fructus Schisandrae Chinensis extrat is made the dosage form pharmaceutically allowing.
10. application according to claim 9, is characterized in that, described dosage form is tablet, hard capsule, soft capsule, powder, tincture, oral liquid, syrup, granule, pill or injection.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410387092.3A CN104138450B (en) | 2014-08-07 | 2014-08-07 | For treating cough and alleviating the Fructus Schisandrae Chinensis extrat of airway inflammation, its preparation method and application |
| PCT/CN2015/076076 WO2016019736A1 (en) | 2014-08-07 | 2015-04-08 | Schisandra extract for treating coughs and alleviating airway inflammations, and preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410387092.3A CN104138450B (en) | 2014-08-07 | 2014-08-07 | For treating cough and alleviating the Fructus Schisandrae Chinensis extrat of airway inflammation, its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104138450A true CN104138450A (en) | 2014-11-12 |
| CN104138450B CN104138450B (en) | 2016-08-03 |
Family
ID=51847902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410387092.3A Active CN104138450B (en) | 2014-08-07 | 2014-08-07 | For treating cough and alleviating the Fructus Schisandrae Chinensis extrat of airway inflammation, its preparation method and application |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN104138450B (en) |
| WO (1) | WO2016019736A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015172613A1 (en) * | 2014-05-16 | 2015-11-19 | 广州医科大学附属第一医院 | Application of fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals used for treating coughing |
| WO2016019736A1 (en) * | 2014-08-07 | 2016-02-11 | 广州医科大学附属第一医院 | Schisandra extract for treating coughs and alleviating airway inflammations, and preparation method and use thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102169920B1 (en) * | 2019-12-20 | 2020-10-26 | 문경시 | A composition comprising extract of Schisandra chinensis, pear and Platycodon grandiflorum for preventing or treating respiratory inflammatory diseases |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100228741B1 (en) * | 1997-01-10 | 1999-11-01 | 한수길 | Solid type-food containing extract of the maximowiczia chinensis fruit |
| CN1435206A (en) * | 2002-01-30 | 2003-08-13 | 贵州仙灵药业股份有限公司 | Sedative jujube kernel capsule |
| CN1830469A (en) * | 2005-03-10 | 2006-09-13 | 香港生物科技研究院有限公司 | Medicine for improving sleep quality and its preparation method |
| CN101450122A (en) * | 2008-12-30 | 2009-06-10 | 南京中医药大学 | Traditional Chinese medicine preparation for treating insomnia and preparation method and use thereof |
| CN102188519A (en) * | 2011-05-09 | 2011-09-21 | 南京中医药大学 | Chinese medicinal compound preparation for treating hepatic fibrosis and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101721488B (en) * | 2009-12-08 | 2011-11-09 | 湖南省中药提取工程研究中心有限公司 | Pharmaceutical composition for treating liver diseases and prepration method thereof |
| CN104138450B (en) * | 2014-08-07 | 2016-08-03 | 广州医科大学附属第一医院 | For treating cough and alleviating the Fructus Schisandrae Chinensis extrat of airway inflammation, its preparation method and application |
-
2014
- 2014-08-07 CN CN201410387092.3A patent/CN104138450B/en active Active
-
2015
- 2015-04-08 WO PCT/CN2015/076076 patent/WO2016019736A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100228741B1 (en) * | 1997-01-10 | 1999-11-01 | 한수길 | Solid type-food containing extract of the maximowiczia chinensis fruit |
| CN1435206A (en) * | 2002-01-30 | 2003-08-13 | 贵州仙灵药业股份有限公司 | Sedative jujube kernel capsule |
| CN1830469A (en) * | 2005-03-10 | 2006-09-13 | 香港生物科技研究院有限公司 | Medicine for improving sleep quality and its preparation method |
| CN101450122A (en) * | 2008-12-30 | 2009-06-10 | 南京中医药大学 | Traditional Chinese medicine preparation for treating insomnia and preparation method and use thereof |
| CN102188519A (en) * | 2011-05-09 | 2011-09-21 | 南京中医药大学 | Chinese medicinal compound preparation for treating hepatic fibrosis and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 严雪梅等: "咳喘灵II号糖浆治疗小儿支气管炎痰湿蕴肺型100例临床观察", 《中国民族民间医药》 * |
| 许元明等: "木兰科植物的研究进展", 《绿色科技》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015172613A1 (en) * | 2014-05-16 | 2015-11-19 | 广州医科大学附属第一医院 | Application of fructus schisandrae total polysaccharides in preparation of medicine or nutraceuticals used for treating coughing |
| WO2016019736A1 (en) * | 2014-08-07 | 2016-02-11 | 广州医科大学附属第一医院 | Schisandra extract for treating coughs and alleviating airway inflammations, and preparation method and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016019736A1 (en) | 2016-02-11 |
| CN104138450B (en) | 2016-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102512495B (en) | Allergic cough oral liquid | |
| CN104027529A (en) | Traditional Chinese medicine composition for regulating blood lipids, blood pressure and blood glucose and preparation method thereof | |
| US10744152B2 (en) | Application of Asarum total polysaccharides in preparation of medicine for treating cough | |
| CN1318071C (en) | Chinese medicine preparation for treating bronchitis | |
| CN104138450B (en) | For treating cough and alleviating the Fructus Schisandrae Chinensis extrat of airway inflammation, its preparation method and application | |
| CN102670977B (en) | Chinese medicinal composition for treating arthralgia, preparation method and applications of Chinese medicinal composition | |
| CN104042720A (en) | Traditional Chinese medicine for preventing and treating diabetes with depression and application of traditional Chinese medicine | |
| CN104491372A (en) | Radix scrophulariae buccal tablet | |
| CN103463244A (en) | Method for extracting blood sugar lowering substance from China roses and application of blood sugar lowering substance | |
| CN103989762B (en) | Chinese medicine composition of internal organs relieving cough and resolving phlegm and preparation method thereof is rushed down in a kind of heat clearing away | |
| CN103977019B (en) | Fruit of Chinese magnoliavine total starches is used for treating the application in the medicine of cough or health products in preparation | |
| CN103977076A (en) | Application of total schisandra lignans in preparation of medicaments or health-care products for treating cough | |
| CN101391043B (en) | Traditional Chinese medicine polysaccharide extract for suppressing lung cancer A549 cell proliferation and preparation method thereof | |
| CN104840737A (en) | Traditional Chinese medicine composition with qi invigorating and lung moistening functions and preparation method and application thereof | |
| CN104095912A (en) | Traditional Chinese medicine formula for treating rheumatism bone disease and preparation method of Chinese patent medicine of traditional Chinese medicine formula | |
| CN108272917A (en) | A kind of Uygur medicine composition and preparation method thereof for treating failure of memory | |
| CN114470110B (en) | Anti-rhinitis traditional Chinese medicine composition with pain relieving effect | |
| CN107582898A (en) | A kind of antibechic stops pharmaceutical composition of phlegm and its production and use | |
| JP6708916B1 (en) | Zhuang family pharmaceutical composition for regulating replenishment and method for preparing the same | |
| CN108888731B (en) | Pharmaceutical composition for relieving cough and reducing sputum | |
| CN107753628A (en) | A kind of Chinese medicine composition and preparation method for treating insomnia | |
| CN103961517A (en) | Medical composition for treating cold and preparation method thereof | |
| CN104013699B (en) | Pharmaceutical composition for treating hypertension caused by hyperactivity of liver-yang | |
| CN101342280B (en) | Chinese medicine externally used paste for curing bronchial asthma and preparation method thereof | |
| CN106063924A (en) | A kind of plant extract treating cough and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |